Allergy Therapeutics (LON:AGY) Hits New 12-Month High – What’s Next?

Allergy Therapeutics plc (LON:AGY) hit a new 52-week high during mid-day trading on Monday . The company traded as high as GBX 12 and last traded at GBX 12, with a volume of 42316 shares changing hands. The stock had previously closed at GBX 11.25.

Allergy Therapeutics Stock Up 6.7%

The company has a debt-to-equity ratio of 835.48, a quick ratio of 1.48 and a current ratio of 1.63. The company has a market cap of £736.97 million, a P/E ratio of -16.67, a P/E/G ratio of -30.70 and a beta of 1.40. The stock has a 50 day moving average price of GBX 9.54 and a 200 day moving average price of GBX 8.59.

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.